Majority of cosmetic practitioners in the UK are not qualified medical doctors, study finds

SAN DIEGO — Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting toxicity,

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

Eli Lil­ly said its rev­enues in the sec­ond quar­ter jumped 28% year-over-year due to growth from its type 2 di­a­betes drug Moun­jaro, breast can­cer treat­ment